

Course analysis (course evaluation)

| | | |
|--------------------------------------|--|---------------------------|
| Course code 1BI049 | Course title Molecular Medicine - Oncology | Credits 15 ECTS |
| Semester (VT/HT-yr) Autumn | Dates 2025-09-01 – 2025-10-30 | |

| | |
|--|--|
| Course Director Per Hydbring (PH) and Ourania Kostopoulou (OK) | Examiner Per Hydbring (PH) |
| Teachers in charge of different parts of the course Per Hydbring and Ourania Kostopoulou (PBLs) Sylvain Puget, Ali Rihani, Aleksandra Krstic (Labs), Mahmood Ul Hassan (Biostatistics) | Other participating teachers A range of teachers, both from within and outside the Onk-Pat and MTC, including both clinicians and researchers (from both KI and KS). |

| | | |
|---|--|--|
| Number of registered students at the 3-week check 51 | Number passed at final course day 49 | Response frequency course valuation survey 31 (60.78%) |
| Other methods for student influence (in addition to the final course valuation/survey) Students had several opportunities to share their thoughts about the course. The coordinators (PH and OK), who attended every lecture in both formats, gathered student impressions informally before and after the sessions. Students were also reminded that they could share their opinions through the class representatives, who would bring these points forward during the course council meeting held later in the term. | | |
| Feedback reporting of the course evaluation results to the students The course directors (PH and OK) consistently communicated the results of previous course evaluations to the students, beginning with an overview during the introductory session and revisiting these findings at the course council. They also took time to meet with students individually on several occasions, discussing the course design and how it had been refined over the years. | | |

Note that...

The analysis should (together with a summarising quantitative summary of the students' course evaluation) be communicated to the education committee at the department responsible for the course and for programme courses also to the programme coordinating committee.

The analysis was communicated to the education committee on the following date: 2026-01-xx
 The analysis was communicated to the programme coordinating committee on the following date: 2026-01-xx

1. Description of any changes implemented since the previous course occasion based on the views of former students

- Lecturers:** New lecturers were introduced to the course to introduce the topics of DNA replication and repair as well as microRNAs in cancer.

- Lab 2 planning:** Protocol for Lab 2 was modified for clarity.

2. Brief summary of the students' evaluation of the course

(Based on the students' quantitative responses to the course valuation and key views from free text responses. Quantitative summary and any graphs are attached.)

- The feedback was highly positive (we could say excellent-high score in all parts and especially in the overall impression of the course). Students valued the organisation and structure of the course and expressed strong appreciation for the involvement of patients.
- Students also provided some constructive comments, including: (i) concerns about importance of LAB 3, (ii) dissatisfaction with the Biostatistics week, (iii) and some lectures.

3. The Course Director's reflections on the implementation and results of the course

Strengths of the course:

The course's major strengths lie in its strong translational focus, seamlessly integrating both basic science and clinical research perspectives. All lecturers are recognized experts in their fields, which greatly enriches the learning experience. In addition, the patient seminars and interviews are highly valued, as they allow students to engage directly with cancer patients and gain a meaningful connection to clinical practice. Students also appreciated directors' presence in all lectures.

Weaknesses of the course:

One of the challenges of the course is that it is spread across three different departments, with labs and the biostatistics component organized by the Departments of Microbiology, Tumor and Cell Biology, and Environmental Medicine, respectively. This division creates difficulties. For instance, if the Biostatistics week were coordinated by the Department of Oncology-Pathology instead, which has the possibility to do so, it could improve communication, also it can give to the students more translation-biological meaning to that week.

3. Other views

The course evaluation highlighted strong leadership and organization (5.1 score in 6). The program successfully balances the biological and clinical components of molecular oncology, while the arrangement and number of lectures, PBL sessions, seminars, and lab exercises are well received. Additionally, patient participation remains a highly valued element, providing students with important real-world insights.

4. Course Director's conclusions and any suggestions for changes

The 2025 MM-O course outcomes are encouraging and support its continued implementation, thanks to the course's solid structure and organization. Based on feedback from both students and instructors, several points will be considered for improvement next year:

- Replacements of some lectures and suggestions to some lecturers for clearer/defined intended learning outcomes
- Suggestion to remove LAB 3, which content is redundant, and add additional seminars/patient demos
- Suggestion/plan to organize the biostatistics week through Onc-Pat

Appendices:

N/A